Condition
Lung Adenocarcinoma|Ovarian Cancer|Peritoneal Carcinoma|Fallopian Tube Cancer|Mesotheliomas Pleural|Mesothelioma Peritoneum
Estimated Enrollment: 30
Age Group: 18 Years and older (Adult, Senior)
Gender: All
Study Type: Interventional
Study Design Allocation: Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: No masking|Primary Purpose: Treatment
Study ID Numbers: 826085
Study First Received: February 9, 2017
Last Updated: February 10, 2017
Estimated Primary Completion Date: March 2021
Primary Outcome Measures:
Number of participants with treatment-related adverse events as assessed by CTCAE v4.03|Clinical anti-tumor effect by standard criteria (RECIST)|Clinical anti-tumor effect by standard criteria [modified RECIST for mesothelioma]|Progression-free survival|Progression overall survival
Sponsors and Collaborators:
University of Pennsylvania
Website Link: https://ClinicalTrials.gov/show/NCT03054298
